First-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of SAR247799, a selective G-protein-biased sphingosine-1 phosphate receptor-1 agonist for endothelial protection.

British Journal of Clinical Pharmacology
Luc BergougnanAshfaq A Parkar

Abstract

SAR247799 is a selective G-protein-biased sphingosine-1 phosphate receptor-1 (S1P1 ) agonist with potential to restore endothelial function in vascular pathologies. SAR247799, a first-in-class molecule differentiated from previous S1P1 -desensitizing molecules developed for multiple sclerosis, can activate S1P1 without desensitization and consequent lymphopenia. The aim was to characterize SAR247799 for its safety, tolerability, pharmacokinetics and pharmacodynamics (activation and desensitization). SAR247799 was administered orally to healthy subjects in a double-blind, randomized, placebo-controlled study with single (2.5-37.5 mg) or 2-week once-daily (0.5-15 mg) doses. An open-label single dose pilot food-interaction arm with 10 mg SAR247799 in cross-over design was also performed. SAR247799 was well tolerated and, at the higher end of the dose ranges, caused the expected dose-dependent pharmacodynamics associated with S1P1 activation (heart rate reduction) and S1P1 desensitization (lymphocyte count reduction). SAR247799 demonstrated dose-proportional increases in exposure and was eliminated with an apparent terminal half-life of 31.2-33.1 hours. Food had a small effect on the pharmacokinetics of SAR247799. SAR247799 had a l...Continue Reading

References

Apr 20, 2004·British Journal of Clinical Pharmacology·John M KovarikGerolf Kraus
Jan 13, 2006·American Journal of Physiology. Renal Physiology·Alaa S AwadMark D Okusa
Oct 26, 2006·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·M SalvadoriUNKNOWN FTY720 0124 Study Group
May 29, 2007·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Timm H WesthoffKlemens Budde
Jan 19, 2010·American Journal of Respiratory Cell and Molecular Biology·Barry S SheaAndrew M Tager
Jan 22, 2010·The New England Journal of Medicine·Ludwig KapposUNKNOWN FREEDOMS Study Group
Mar 1, 2012·Neurology·Nieraj Jain, M Tariq Bhatti
Aug 1, 2012·British Journal of Clinical Pharmacology·Eric LegangneuxDonald Johns
Nov 20, 2013·International Journal of Biological Sciences·Peramaiyan RajendranIkuo Nishigaki
Jul 22, 2014·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·M HochJ Dingemanse
May 12, 2015·Clinica Chimica Acta; International Journal of Clinical Chemistry·Xiao-Dong JingQiang She
Feb 18, 2016·European Journal of Drug Metabolism and Pharmacokinetics·Margaux BoehlerJasper Dingemanse
Apr 27, 2016·Current Atherosclerosis Reports·Teresa Sanchez
May 6, 2016·The New England Journal of Medicine·William J SandbornUNKNOWN TOUCHSTONE Study Group
Apr 12, 2017·Journal of Clinical Pharmacology·Jonathan Q TranPaul A Frohna
Jul 1, 2017·PloS One·Chuchard Punsawad, Parnpen Viriyavejakul
Sep 16, 2017·Clinical Pharmacology and Therapeutics·Dominik LottAndreas Krause

❮ Previous
Next ❯

Citations

Dec 18, 2020·Arteriosclerosis, Thrombosis, and Vascular Biology·Eric EngelbrechtTimothy Hla
Jul 31, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Alexander Kalinkovich, Gregory Livshits

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.